Deep Vein Thrombosis: Symptoms, Risks, and Treatment

Intro

Deep vein thrombosis (DVT) is the formation of a blood clot inside a deep vein — most commonly in the calf, thigh, or pelvis. DVT is part of the broader condition called venous thromboembolism (VTE), which also includes pulmonary embolism (PE) — when a clot dislodges and travels to the lungs.

DVT affects approximately 1–2 per 1,000 adults per year in the general population, with higher rates in hospitalised patients and specific risk groups. It can affect people of all ages but is more common with increasing age and with identifiable risk factors.

Prompt diagnosis and treatment are essential. Anticoagulation reduces the risk of clot extension, PE, and long-term complications significantly. Understanding when to seek assessment is the most important thing a person at risk can do.

Key Points

DVT most commonly occurs in the deep veins of the leg, pelvis, or arm, and symptoms may be absent or mild.
The principal danger of DVT is pulmonary embolism — a medical emergency causing breathlessness, chest pain, and, in severe cases, circulatory collapse.
Risk factors include immobility, surgery, cancer, oestrogen-containing contraceptives, pregnancy, and inherited clotting disorders.
Diagnosis involves clinical risk scoring (Wells score), D-dimer blood test, and compression ultrasound.
Anticoagulants — direct oral anticoagulants (DOACs) such as rivaroxaban and apixaban are the preferred treatment — prevent clot extension and reduce PE risk.
Treatment duration depends on whether the DVT was provoked (temporary risk factor, 3 months typically) or unprovoked (longer, risk-benefit dependent).
Post-thrombotic syndrome — chronic leg swelling, pain, and skin changes — affects up to 40% of DVT patients and is reduced by appropriate treatment and compression hosiery.

Background

The deep veins are the major venous channels within the muscles and body cavities, as opposed to superficial veins visible beneath the skin. Blood clots in deep veins can partially or completely obstruct blood flow and — crucially — can fragment and travel to the lungs.

Venous thromboembolism (VTE) is the collective term for DVT and pulmonary embolism. These conditions share the same pathophysiology, risk factors, and treatment principles and are managed as a single disease spectrum.

Virchow’s Triad

Three factors predispose to venous clot formation, first described by Rudolf Virchow:

Venous stasis — slowed blood flow, as in immobility, heart failure, or obstruction
Hypercoagulability — increased clotting tendency, from inherited thrombophilia, malignancy, pregnancy, or oestrogen
Endothelial injury — damage to the vessel wall from surgery, trauma, or inflammation

In most DVTs, more than one factor is present.

Causes and Risk Factors

Provoked DVT

DVT is described as provoked when it occurs in the context of a clearly identifiable transient or persistent risk factor:

Transient (time-limited) risk factors:

Major surgery (especially orthopaedic surgery — hip/knee replacement, lower limb fracture repair)
Hospital admission with immobility
Long-haul travel (>4 hours) with prolonged sitting
Significant trauma or injury
Pregnancy and the 6 weeks postpartum
Acute medical illness with immobilisation

Persistent risk factors:

Active cancer (cancer significantly increases clotting risk and is a major driver of unprovoked-appearing VTE)
Inflammatory bowel disease
Autoimmune conditions
Chronic heart failure or severe respiratory disease

Unprovoked DVT

When no provoking risk factor is identified, DVT is described as unprovoked. Unprovoked DVT has a higher risk of recurrence and warrants consideration of underlying malignancy, thrombophilia testing, and longer anticoagulation.

Inherited thrombophilia

Genetic clotting disorders increase DVT risk:

Factor V Leiden mutation — most common; reduces sensitivity of clotting factor V to inactivation
Prothrombin G20210A mutation
Protein C or S deficiency
Antithrombin deficiency

Acquired thrombophilia includes antiphospholipid syndrome — relevant in recurrent VTE and pregnancy loss.

Symptoms

Classic DVT symptoms in the leg:

Unilateral swelling of the calf, ankle, or entire leg
Pain or tenderness in the calf or thigh — may feel like a cramp or ache
Warmth over the affected area
Redness or skin discolouration
Distended superficial veins

Importantly, DVT is frequently silent — up to 50% of cases cause no symptoms. Conversely, similar symptoms can arise from other causes (muscle strain, Baker’s cyst, cellulitis, superficial thrombophlebitis), so clinical assessment is always necessary.

Pulmonary embolism — when to seek emergency care

If DVT dislodges and travels to the lungs, symptoms of PE include:

Sudden onset breathlessness
Sharp chest pain, often worse on breathing in (pleuritic)
Coughing, sometimes with blood-streaked sputum
Rapid heart rate
Light-headedness or fainting
In severe cases: collapse, very low blood pressure, blue lips or fingertips

Suspected pulmonary embolism is a medical emergency — call emergency services immediately.

Diagnosis

Clinical probability: the Wells Score

The Wells DVT score estimates the likelihood of DVT before testing:

Clinical feature	Score
Active cancer	+1
Paralysis, paresis, or plaster immobilisation	+1
Recently bedridden ≥3 days, or major surgery in past 12 weeks	+1
Localised tenderness along deep vein distribution	+1
Entire leg swollen	+1
Calf swelling >3 cm compared with asymptomatic leg	+1
Pitting oedema (greater in the symptomatic leg)	+1
Collateral superficial veins (non-varicose)	+1
Alternative diagnosis as likely or more likely than DVT	–2

Score ≥2: DVT likely. Score <2: DVT unlikely.

D-dimer

D-dimer is a fibrin degradation product elevated when clotting is active. In low-probability patients, a negative D-dimer effectively rules out DVT without further testing.

However, D-dimer is non-specific — it is elevated in pregnancy, infection, inflammation, cancer, and after surgery. A positive D-dimer does not confirm DVT and always requires imaging.

Compression ultrasound

Compression duplex ultrasound is the primary imaging modality for DVT diagnosis. A normal (compressible) vein on ultrasound rules out DVT in the segment examined. The test is non-invasive, widely available, and does not involve radiation.

In proximal DVT (above knee), sensitivity exceeds 95%. Distal (calf) DVT is harder to detect; a repeat scan in 5–7 days may be recommended if clinical suspicion remains.

Treatment

Anticoagulation

Anticoagulation is the cornerstone of DVT treatment. It does not dissolve existing clot but prevents extension and reduces PE risk while the body’s own fibrinolytic system resolves the clot.

Direct oral anticoagulants (DOACs) are now preferred:

Drug	Mechanism	Dosing note
Rivaroxaban	Factor Xa inhibitor	15mg twice daily for 3 weeks, then 20mg once daily
Apixaban	Factor Xa inhibitor	10mg twice daily for 7 days, then 5mg twice daily
Dabigatran	Direct thrombin inhibitor	Requires initial parenteral anticoagulation
Edoxaban	Factor Xa inhibitor	Requires initial parenteral anticoagulation

DOACs are preferred over warfarin for most DVTs: fixed dosing, no routine monitoring, fewer food/drug interactions, and at least as effective with similar or lower bleeding risk.

Warfarin — still used where DOACs are not suitable (severe renal impairment, antiphospholipid syndrome, some heart valve conditions). Requires INR monitoring; target INR 2.0–3.0.

Low molecular weight heparin (LMWH) — subcutaneous injection; preferred for DVT in pregnancy (warfarin and DOACs are teratogenic/harmful in pregnancy) and in many cancer-associated VTEs.

Treatment duration

DVT type	Typical duration
Provoked by a transient risk factor	3 months
Unprovoked first DVT	At least 3–6 months; consider extended if recurrence risk outweighs bleeding risk
Recurrent DVT	Usually extended (indefinite) anticoagulation
Cancer-associated DVT	Extended, ongoing as long as cancer active; LMWH or DOAC

Compression hosiery

Graduated elastic compression stockings (class 2, below-knee) reduce swelling and may help prevent post-thrombotic syndrome when used for at least 2 years after DVT. Their benefit in preventing post-thrombotic syndrome has been debated in recent trials, but they are still recommended for symptomatic leg swelling.

Thrombolysis and catheter-directed therapy

In massive proximal DVT with limb-threatening ischaemia (phlegmasia cerulea dolens), or for high-risk PE with haemodynamic instability, catheter-directed thrombolysis or systemic thrombolysis may be considered. These are specialist decisions.

Prevention

Preventing DVT is particularly important in high-risk settings:

Hospital inpatients — all admitted patients should have VTE risk assessed; thromboprophylaxis with LMWH and/or mechanical compression (anti-embolism stockings, pneumatic compression devices) is standard practice.
Surgery — anticoagulation before and after major surgery (particularly orthopaedic) is evidence-based; typically continued for 10–35 days post-operatively.
Long-haul travel — staying hydrated, moving regularly, calf exercises, avoiding alcohol; compression stockings for those at elevated risk; LMWH for very high risk (prior VTE, active cancer, thrombophilia).
Oral contraceptives / HRT — combined oestrogen-progestogen pills increase VTE risk 3–4 fold; risk-benefit assessment is important in those with additional risk factors. Progestogen-only or non-hormonal options may be preferred.
Pregnancy — VTE risk is highest in the first trimester and postpartum; thromboprophylaxis with LMWH is recommended for high-risk pregnancies.

Risks, Benefits, and Prognosis

Most people treated promptly for DVT recover well. Key long-term considerations:

Recurrence — after stopping anticoagulation, the annual recurrence risk is approximately 5–10% after unprovoked DVT; lower after provoked DVT.
Post-thrombotic syndrome — affects 20–50% of DVT patients. Presents as chronic leg heaviness, swelling, skin discolouration, and in severe cases, venous ulceration. Risk is higher with proximal DVT and with recurrent ipsilateral DVT. Compression hosiery and adequate initial anticoagulation reduce risk.
PE mortality — untreated symptomatic PE carries approximately 30% mortality; with prompt treatment this falls to 1–8% depending on severity.
Bleeding risk — anticoagulants increase bleeding risk (gastrointestinal, intracranial). Annual major bleeding risk on therapeutic anticoagulation is approximately 1–3%. The risk-benefit calculation guides treatment duration decisions.

FAQ

Q: Can DVT happen in arms? A: Yes. Upper extremity DVT (axillary or subclavian vein) accounts for about 5–10% of DVTs. It can occur spontaneously (effort-related, particularly in young athletes) or be catheter-related (central venous lines are a common cause). Treatment principles are similar to lower-limb DVT.

Q: I had DVT years ago — do I need to worry about flying? A: A history of DVT, particularly unprovoked, increases the risk of another event. If you are no longer on anticoagulation, discuss with your doctor before long-haul travel. Options include compression stockings, aspirin (evidence limited), and, for high-risk individuals, a single prophylactic dose of LMWH before a very long flight.

Q: Do I need to test family members for thrombophilia? A: Thrombophilia testing of relatives is sometimes recommended after provoked DVT in certain high-risk inherited conditions. However, testing is not universally recommended as it does not always change management and can cause anxiety. Your haematologist or thrombosis clinic can advise based on family history and the specifics of your clot.

Q: How quickly does DVT treatment work? A: Anticoagulation prevents clot extension almost immediately. Symptoms (swelling, pain) may take days to weeks to fully improve as the body reabsorbs the clot. Some residual swelling may persist for months. Complete clot resolution varies from weeks to months.

Q: Can I exercise with DVT? A: Moderate activity (walking) is generally safe and encouraged once treatment has started; it helps circulation and reduces swelling. Strenuous exercise should be avoided early in treatment. Compression stockings help with symptoms during activity.